Jefferies resumed coverage on Waldencast plc with a new price target
$WALD
Package Goods/Cosmetics
Consumer Discretionary
Jefferies resumed coverage of Waldencast plc with a rating of Buy and set a new price target of $2.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2026 | $2.00 | Buy | Jefferies |
| 11/25/2025 | $3.00 | Outperform → Market Perform | Telsey Advisory Group |
| 4/22/2025 | $5.00 | Buy | Alliance Global Partners |
| 12/16/2024 | $4.30 | Hold | TD Cowen |
| 10/25/2024 | $5.00 | Buy | Canaccord Genuity |
| 5/1/2024 | $10.00 → $8.00 | Outperform | Telsey Advisory Group |
| 7/24/2023 | Outperform → Mkt Perform | Raymond James | |
| 9/9/2022 | $12.00 | Buy | DA Davidson |
Jefferies resumed coverage of Waldencast plc with a rating of Buy and set a new price target of $2.00
Telsey Advisory Group downgraded Waldencast plc from Outperform to Market Perform and set a new price target of $3.00
Alliance Global Partners initiated coverage of Waldencast plc with a rating of Buy and set a new price target of $5.00
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat
FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o
LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned
3 - Waldencast plc (0001840199) (Issuer)
3 - Waldencast plc (0001840199) (Issuer)
3 - Waldencast plc (0001840199) (Issuer)
6-K - Waldencast plc (0001840199) (Filer)
20-F - Waldencast plc (0001840199) (Filer)
6-K - Waldencast plc (0001840199) (Filer)
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat
Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St
The New York City based award-winning clean color cosmetics brand will expand to select Ulta Beauty stores nationwide and online, marking a significant milestone since its debut in 2016 NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Milk Makeup, the trailblazing clean beauty brand celebrated for its iconic, high-performance formulas, inclusive ethos and part of the Waldencast plc (NASDAQ:WALD) platform, is thrilled to announce an expansion into the nation's largest beauty retailer, Ulta Beauty. Beginning this spring, Milk Makeup's cult-favorite products, including the 13x award-winning Hydro Grip Primer and internet-breaking Cooling Water Jelly Tints will be available in 600+ Ulta Beauty stores nat
FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o
LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned
Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue Contrasted performance for Milk Makeup with Q2 2025 net revenue growth driven by U.S. channel expansion and sell-out acceleration but softer performance in Q3 2025 in international markets Company advances key strategic initiatives, including expansion into medical aesthetics through the Novaestiq acquisition and strengthened balance sheet following the sale of the Obagi Japan trademark and credit facility refinancing Waldencast updates FY 2025 guidance to reflect current trends and purposeful investments to drive long-term growth LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NA
SC 13D/A - Waldencast plc (0001840199) (Subject)
SC 13G - Waldencast plc (0001840199) (Subject)
SC 13G/A - Waldencast plc (0001840199) (Subject)